Genetic Technologies Ltd
ASX:GTG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genetic Technologies Ltd
Common Shares Outstanding
Genetic Technologies Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genetic Technologies Ltd
ASX:GTG
|
Common Shares Outstanding
AU$145.4m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
-17%
|
|
|
Anteotech Ltd
ASX:ADO
|
Common Shares Outstanding
AU$2.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
Common Shares Outstanding
AU$163.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
Common Shares Outstanding
AU$152.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Cryosite Ltd
ASX:CTE
|
Common Shares Outstanding
AU$48.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
Common Shares Outstanding
AU$47.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Genetic Technologies Ltd
Glance View
Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company is headquartered in Melbourne, Victoria. The firm is focused on the development and commercialization of genetic risk assessment technology. The firm is engaged in providing genomics-based tests in health, wellness and serious disease through its GeneType and EasyDNA brands. GTG is focused on developing an integrated predictive genetic testing and assessment tools enabling medical practitioners and their patients to proactively manage health. The Company’s geneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. The GeneType offers integrated risk testing for a range of serious conditions. GTG offers cancer predictive testing and assessment tools for physicians. Its Polygenic Risk Scores (PRS) platform offers integrated clinical and genetic risk delivering actionable outcomes from physicians and individuals.
See Also
What is Genetic Technologies Ltd's Common Shares Outstanding?
Common Shares Outstanding
145.4m
AUD
Based on the financial report for Dec 31, 2024, Genetic Technologies Ltd's Common Shares Outstanding amounts to 145.4m AUD.
What is Genetic Technologies Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
-17%
Over the last year, the Common Shares Outstanding growth was 20%. The average annual Common Shares Outstanding growth rates for Genetic Technologies Ltd have been -75% over the past three years , -49% over the past five years , and -17% over the past ten years .
